论文部分内容阅读
目的探讨乳腺导管内癌与浸润性导管癌组织中C-erbB-2,ER,PR表达的差异。方法应用免疫组化法检测34例乳腺导管内癌及40例浸润性导管癌中C-erbB-2,ER,PR表达。结果乳腺导管内癌中C-erbB-2,ER,PR阳性表达率分别为44.1%,58.8%,55.9%,而在浸润性导管癌中分别为52.5%,55%和62.5%。上述3种标记物的表达在两类型癌间均无统计学差异。结论C-erbB-2,ER,PR在乳腺导管内癌与浸润性导管癌中的表达相似,它们可望作为乳腺癌预后和疗效的指标。
Objective To investigate the expression differences of C-erbB-2, ER and PR in breast ductal carcinoma and invasive ductal carcinoma. Methods The expressions of C-erbB-2, ER and PR in 34 cases of intraductal carcinoma and 40 cases of invasive ductal carcinoma were detected by immunohistochemistry. Results The positive rates of C-erbB-2, ER and PR in intraductal carcinoma were 44.1%, 58.8% and 55.9% respectively, while they were 52.5%, 55% and 62.5% respectively in invasive ductal carcinoma. There was no significant difference in the expression of these three markers between the two types of cancer. Conclusions The expression of C-erbB-2, ER and PR in ductal carcinoma of the duodenum is similar to that in invasive ductal carcinoma, which is expected to serve as an indicator of the prognosis and efficacy of breast cancer.